MedTrace Logo

tDCS & Auditory Hallucinations in Schizophrenia

NCT02227563 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2016-11-02

No results posted yet for this study

Summary

The aim of this study is to evaluate tDCS effects on schizophrenia symptoms, particularly on auditory verbal hallucinations. tDCS applied with cathodal (inhibitory) electrode over the left temporal parietal junction and anodal (excitatory) electrode over the left dorsolateral prefrontal cortex.

Conditions

Interventions

DEVICE

Active tDCS

repetitive daily tDCS sessions for a period of one week

DEVICE

control

Sponsors & Collaborators

  • Herzog Hospital

    lead OTHER

Principal Investigators

  • Oded Meiron, PhD · Sarah Herzog Memorial Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2016-08-31
Completion
2016-08-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02227563 on ClinicalTrials.gov